The Sjogren’s syndrome treatment market size was estimated to be worth USD 311.7 million. The market is expected to rise at a growth rate of 4.0% in the forecast period of 2024-2032, and by 2032, the market value is anticipated to be worth USD 427.3 million. The growing number of Sjogren’s syndrome cases and increasing awareness are the primary market drivers.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Sjogren syndrome is a chronic autoimmune disorder. This syndrome mainly affects the mouth and eye glands by reducing the amount of moisture produced by them. Depending on the development and origin, Sjogren’s syndrome is of two types- primary and secondary.
The exact cause of Sjogren’s syndrome is still unclear, but it is mainly assumed to be an autoimmune disorder. The other anticipated causes of Sjogren’s syndrome include genetic and environmental factors, sex hormones, and other viral infections.
The common signs and symptoms include dry eyes, dry mouth, muscle pain, joint pain, blurred vision, vaginal dryness, dry skin, tooth decay, dry cough, and sensation in the eyes.
Sjogren’s syndrome is diagnosed through various diagnostic tools and procedures, including blood tests, biopsy, eye exams, and imaging tests.
There is no approved treatment for the eradication of Sjogren’s syndrome, yet different therapeutic interventions have been proven beneficial for managing the symptoms. Eye drops, artificial tear solutions and autologous serum drops are generally used for treating ocular symptoms. Saliva producers and oral prescription medications are incorporated for the management of dry mouth. Depending on the symptoms, there is a change in the treatment regimen accordingly.
According to the Sjogren’s syndrome treatment market research report, the market can be categorised into the following segments:
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Breakup by Drug Class
Market Breakup by Indication Type
Market Breakup by Therapeutic Agents
Sjogren’s Syndrome Treatment Market Breakup by Route of Administration
Market Breakup by Distribution Channel
Market Breakup by Region
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The growth of the Sjogren’s syndrome treatment market is driven by the rising number of Sjogren’s syndrome cases. The rise in the cases of the associated diseases that cause Sjogren’s syndrome can also be attributed to the growth of this treatment market. With the growing geriatric population, the risk and severity of the disease also increases.
Increasing research and developmental activities and flexible government initiatives are also contributing to the market growth. The rising awareness and better understanding of the entire scenario are also facilitating the market development.
Most of the therapeutic interventions are in clinical trials and can be incorporated as innovative treatments in disease management once approved. With time, novel companies are entering into mergers and acquisitions with other companies to expand their product portfolio. This will increase sales and profits and propel market growth and development.
North America is expected to dominate the market owing to its higher prevalence rate and advanced healthcare infrastructure facilities.
The Asia Pacific region is anticipated to be the fastest-growing region due to the rising geriatric population, developing healthcare infrastructure, and increasing economies. The flexible government policies and rising government spending in the healthcare sector are also contributing to Sjogren’s syndrome treatment market growth in this region.
The exact diagnosis of Sjogren’s syndrome is a bit difficult and often leads to several complications. The treatment for this syndrome depends on the affected part of the body. The initial symptoms, such as dry eyes or dry mouth, are managed by using over-the-counter eye drops at regular intervals. For the management of serious conditions, prescription medications and surgical procedures are considered suitable treatment options.
Prescription eyedrops like Cyclosporin and Lifitegrast are considered the first-line treatment for the alleviation of eye inflammation and other ocular symptoms. Other common symptoms like dry mouth are treated using the drugs pilocarpine and cevimeline which facilitate saliva production in the mouth. General drugs, such as Methotrexate and Hydroxychloroquine are used to treat the systemwide symptoms.
A surgical procedure is the last treatment option in severe cases. It is a minimally invasive procedure to seal the tear ducts that are responsible for tear drainage in the eyes. Collagen or silicone plugs are placed into the ducts to stop the tear drainage.
Several homecare remedies such as the application of artificial tears gels and ointments help in the alleviation of the symptoms. Preventative measures, such as increasing fluid intake and maintaining oral hygiene, are also helpful in the syndrome prevention.
Several clinical trials for Sjogren’s syndrome are being developed and researched by healthcare organisations and pharma companies. To get a safer and more efficient treatment for Sjogren’s syndrome, investigators continuously search, analyse, and reformulate current therapies and treatments. They are more drawn toward the study of the new treatment with new targeted therapies.
Current management techniques are mainly empirical and provide only symptomatic relief for patients. The clinical studies are primarily focused on novel methods to treat B cells and co-stimulation targets.
Horizon therapeutics, a key market player, is evaluating dazodalibep under Phase II clinical trials for treating modern to high systemic disease activity. This drug is designed to block the interaction between CD-40 and its receptor, thus managing its autoimmune activity.
Ianalumab, an exploratory drug has also shown potential effects under Phase II clinical trials. The drug has exhibited improved results in the Sjogren’s syndrome disease activity index score and health-related quality of life.
Telicacept, another experimental drug, is being discovered by RemeGen for treating the primary Sjogren’s syndrome. This drug is in Phase II trials and contains two parts, an antibody called immunoglobin G and part of a protein known as TACI. Several ongoing clinical trials are also propelling the growth of the market growth.
The report gives an in-depth analysis of the key players involved in the Sjogren’s syndrome treatment market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:
|Scope of the Report||
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|Breakup by Drug Class||
|Breakup by Indication Type||
|Breakup by Therapeutic Agents||
|Breakup by Route of Administration||
|Breakup by Distribution Channel||
|Breakup by Region||
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
2 Research Methodology
3 Executive Summary
4 Sjogren’s Syndrome Overview
4.1 Guidelines and Stages
4.3 Screening and Diagnosis
4.4 Treatment Pathway
5 Patient Profile
5.1 Patient Profile Overview
5.2 Patient Psychology and Emotional Impact Factors
5.3 Risk Assessment and Treatment Success Rate
6 Current Scenario Evaluation and Regulatory Framework
6.1 Emerging Therapies and Clinical Trials Synopsis
6.2 Patent Landscape
6.2.1 Patent Overview
188.8.131.52 Patent Status and Expiry
184.108.40.206 Timelines from Drug Development to Commercial Launch
220.127.116.11 New Drug Application
18.104.22.168.1 Documentation and Approval Process
6.3 Cost of Treatment
6.4 Regulatory Framework
6.4.1 Regulatory Overview
22.214.171.124 US FDA
126.96.36.199 EU EMA
188.8.131.52 INDIA CDSCO
184.108.40.206 JAPAN PMDA
7 Challenges and Unmet Needs
7.1 Treatment Pathway Challenges
7.2 Compliance and Drop-Out Analysis
7.3 Awareness and Prevention Gaps
8 Global Sjogren’s Syndrome Treatment Market
8.1 Global Sjogren’s Syndrome Treatment Market Overview
8.2 Global Sjogren’s Syndrome Treatment Market Analysis
8.2.1 Market Overview
220.127.116.11 Global Sjogren’s Syndrome Treatment Market Historical Value (2017-2023)
18.104.22.168 Global Sjogren’s Syndrome Treatment Market Forecast Value (2024-2032)
8.3 Global Sjogren’s Syndrome Treatment Market by Drug Class
8.3.1 Market Overview
22.214.171.124 Cholinergic Agonists
126.96.36.199.1 Salagen (Pilocarpine Hydrochloride)
188.8.131.52.2 Evoxac (Cevimeline Hydrochloride)
184.108.40.206 Off-Label Drugs
220.127.116.11.1 Tear and Saliva Substitutes
18.104.22.168.2 Cyclosporine Ophthalmic Emulsions – Restasis, Ikervis, Papilock Mini
22.214.171.124.3 Topical Ophthalmic Corticosteroids – Prednisolone, Fluorometholone, Loteprednol
126.96.36.199.4 Antimalarial Agents – Hydroxychloroquine
188.8.131.52.5 Other Systemic Immunosuppressive Therapies – Methotrexate, Azathioprine, Cyclophosphamide
184.108.40.206.6 Systemic Corticosteroids – Prednisolone, Methylprednisolone
220.127.116.11.7 Biologic Agents – Rituxan (Rituximab)
8.4 Global Sjogren’s Syndrome Treatment Market by Indication Type
8.4.1 Market Overview
18.104.22.168 Primary Sjogren's Syndrome
22.214.171.124 Secondary Sjogren's Syndrome
8.5 Global Sjogren’s Syndrome Treatment Market by Therapeutic Agents
8.5.1 Market Overview
126.96.36.199 Targeted Drugs
188.8.131.52 Pain Relievers
184.108.40.206 Symptom Modulators
8.6 Global Sjogren’s Syndrome Treatment Market by Route of Administration
8.6.1 Market Overview
8.7 Global Sjogren’s Syndrome Treatment Market by Distribution Channel
8.7.1 Market Overview
220.127.116.11 Retail Pharmacies
18.104.22.168 Hospital Based Pharmacies
22.214.171.124 Online Pharmacies
8.8 Global Sjogren’s Syndrome Treatment Market by Region
8.8.1 Market Overview
126.96.36.199 North America
188.8.131.52 Asia Pacific
184.108.40.206 Latin America
220.127.116.11 Middle East and Africa
9 North America Sjogren’s Syndrome Treatment Market
9.1 Market Share by Country
9.2 United States of America
9.2.1 Historical Trend (2017-2023)
9.2.2 Forecast Trend (2024-2032)
9.3.1 Historical Trend (2017-2023)
9.3.2 Forecast Trend (2024-2032)
10 Europe Sjogren’s Syndrome Treatment Market
10.1 Market Share by Country
10.2 United Kingdom
10.2.1 Historical Trend (2017-2023)
10.2.2 Forecast Trend (2024-2032)
10.3.1 Historical Trend (2017-2023)
10.3.2 Forecast Trend (2024-2032)
10.4.1 Historical Trend (2017-2023)
10.4.2 Forecast Trend (2024-2032)
10.5.1 Historical Trend (2017-2023)
10.5.2 Forecast Trend (2024-2032)
11 Asia Pacific Sjogren’s Syndrome Treatment Market
11.1 Market Share by Country
11.2.1 Historical Trend (2017-2023)
11.2.2 Forecast Trend (2024-2032)
11.3.1 Historical Trend (2017-2023)
11.3.2 Forecast Trend (2024-2032)
11.4.1 Historical Trend (2017-2023)
11.4.2 Forecast Trend (2024-2032)
11.5.1 Historical Trend (2017-2023)
11.5.2 Forecast Trend (2024-2032)
11.6.1 Historical Trend (2017-2023)
11.6.2 Forecast Trend (2024-2032)
12 Latin America Sjogren’s Syndrome Treatment Market
12.1 Market Share by Country
12.2.1 Historical Trend (2017-2023)
12.2.2 Forecast Trend (2024-2032)
12.3.1 Historical Trend (2017-2023)
12.3.2 Forecast Trend (2024-2032)
12.4.1 Historical Trend (2017-2023)
12.4.2 Forecast Trend (2024-2032)
13 Middle East and Africa Sjogren’s Syndrome Treatment Market
13.1 Market Share by Country
13.2 Saudi Arabia
13.2.1 Historical Trend (2017-2023)
13.2.2 Forecast Trend (2024-2032)
13.3 United Arab Emirates
13.3.1 Historical Trend (2017-2023)
13.3.2 Forecast Trend (2024-2032)
13.4.1 Historical Trend (2017-2023)
13.4.2 Forecast Trend (2024-2032)
13.5 South Africa
13.5.1 Historical Trend (2017-2023)
13.5.2 Forecast Trend (2024-2032)
14 Global Sjogren’s Syndrome Treatment Market Dynamics
14.1 Market Drivers and Constraints
14.2 SWOT Analysis
14.3 Porter’s Five Forces Model
14.4 Key Demand Indicators
14.5 Key Price Indicators
14.6 Industry Events, Initiatives & Trends
14.7 Value Chain Analysis
15 Supplier Landscape
15.1 Denali Therapeutics
15.1.1 Company Overview
15.1.2 Product Portfolio
15.1.3 Demographic Reach and Achievements
15.1.4 Mergers and Acquisitions
15.2 Clovis Oncology
15.2.1 Company Overview
15.2.2 Product Portfolio
15.2.3 Demographic Reach and Achievements
15.2.4 Mergers and Acquisitions
15.3 Horizon Therapeutics plc
15.3.1 Company Overview
15.3.2 Product Portfolio
15.3.3 Demographic Reach and Achievements
15.3.4 Mergers and Acquisitions
15.4 Sangamo Therapeutics
15.4.1 Company Overview
15.4.2 Product Portfolio
15.4.3 Demographic Reach and Achievements
15.4.4 Mergers and Acquisitions
15.5 AbbVie Inc.
15.5.1 Company Overview
15.5.2 Product Portfolio
15.5.3 Demographic Reach and Achievements
15.5.4 Mergers and Acquisitions
15.6 Advanz Pharma
15.6.1 Company Overview
15.6.2 Product Portfolio
15.6.3 Demographic Reach and Achievements
15.6.4 Mergers and Acquisitions
15.7 Biogen Inc.
15.7.1 Company Overview
15.7.2 Product Portfolio
15.7.3 Demographic Reach and Achievements
15.7.4 Mergers and Acquisitions
15.8 Bristol-Myers Squibb Company
15.8.1 Company Overview
15.8.2 Product Portfolio
15.8.3 Demographic Reach and Achievements
15.8.4 Mergers and Acquisitions
15.9 Daiichi Sankyo Company, Limited
15.9.1 Company Overview
15.9.2 Product Portfolio
15.9.3 Demographic Reach and Achievements
15.9.4 Mergers and Acquisitions
15.10 Hikma Pharmaceuticals plc
15.10.1 Company Overview
15.10.2 Product Portfolio
15.10.3 Demographic Reach and Achievements
15.10.4 Mergers and Acquisitions
15.11 Johnson and Johnson
15.11.1 Company Overview
15.11.2 Product Portfolio
15.11.3 Demographic Reach and Achievements
15.11.4 Mergers and Acquisitions
15.12 Sanofi S.A.
15.12.1 Company Overview
15.12.2 Product Portfolio
15.12.3 Demographic Reach and Achievements
15.12.4 Mergers and Acquisitions
15.13 Sun Pharmaceutical Industries Limited
15.13.1 Company Overview
15.13.2 Product Portfolio
15.13.3 Demographic Reach and Achievements
15.13.4 Mergers and Acquisitions
15.14 Novartis AG
15.14.1 Company Overview
15.14.2 Product Portfolio
15.14.3 Demographic Reach and Achievements
15.14.4 Mergers and Acquisitions
16 Global Sjogren’s Syndrome Treatment Market- Drug Distribution Model (Additional Insight)
16.2 Potential Distributors
16.3 Key Parameters for Distribution Partner Assessment
17 Payment Methods (Additional Insight)
17.1 Government Funded
17.2 Private Insurance
*Additional insights provided are customisable as per client requirements.
Based on the drug class, the market has been divided into cholinergic agonists and off-label drugs.
Based on the indication type, the market has been segmented into primary and secondary Sjogren’s syndrome.
Based on the treatment method, the market has been categorised into targeted drugs, pain relievers, symptom modulators, and vaccines.
Based on the route of administration, the market is segmented into oral, intravenous, and subcutaneous, among others.
Based on the distribution channels, the market is classified into retail pharmacies, hospital-based pharmacies, and online pharmacies.
The rising number of Sjogren’s syndrome cases, increasing research and development activities and growing mergers and acquisitions are driving the growth of the market.
On a regional level, the market has been classified into North America, Europe, Asia Pacific, Latin America and the Middle East and Africa.
The key companies involved in the market are Denali Therapeutics, Clovis Oncology, Horizon Therapeutics plc, Sangamo Therapeutics, AbbVie Inc., Advanz Pharma, Biogen Inc., Bristol-Myers Squibb Company, Daiichi Sankyo Company, Limited, Hikma Pharmaceuticals plc, Johnson and Johnson, Sanofi S.A., Sun Pharmaceutical Industries Limited, and Novartis AG, among others.
Single User License
Five User License
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.